However, these experiments were performed on HER2+ Skov-3 intraperitoneally injected cell line models, and given the wide variation in HER2 expression in ovarian cancer, more homogenously expressed biomarkers are required to further develop this approach. This evidence concerns the gene ERBB2 and ovarian cancer.